X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (470) 470
Book Review (52) 52
Publication (40) 40
Conference Proceeding (7) 7
Patent (4) 4
Book Chapter (3) 3
Book / eBook (2) 2
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (325) 325
humans (321) 321
female (297) 297
oncology (245) 245
breast cancer (175) 175
breast neoplasms - drug therapy (172) 172
middle aged (132) 132
aged (109) 109
tamoxifen (108) 108
breast neoplasms - genetics (101) 101
breast neoplasms - pathology (101) 101
breast neoplasms - metabolism (87) 87
postmenopausal women (86) 86
adult (74) 74
antineoplastic agents, hormonal - therapeutic use (72) 72
cancer (71) 71
prognosis (71) 71
estrogen (59) 59
postmenopause (58) 58
treatment outcome (56) 56
receptors, estrogen - metabolism (55) 55
endocrine therapy (53) 53
chemotherapy (50) 50
chemotherapy, adjuvant (50) 50
aromatase inhibitors (49) 49
anastrozole (48) 48
research (48) 48
tamoxifen - therapeutic use (48) 48
immunohistochemistry (47) 47
therapy (46) 46
risk factors (44) 44
expression (40) 40
health aspects (39) 39
nitriles - therapeutic use (39) 39
triazoles - therapeutic use (39) 39
gene expression (37) 37
estrogen-receptor (35) 35
letrozole (35) 35
women (35) 35
antineoplastic combined chemotherapy protocols - therapeutic use (34) 34
aged, 80 and over (32) 32
aromatase inhibitors - therapeutic use (32) 32
biomarkers, tumor - analysis (32) 32
gene expression profiling (32) 32
receptor, erbb-2 - metabolism (32) 32
abridged index medicus (31) 31
antineoplastic agents, hormonal - pharmacology (31) 31
combination (31) 31
endocrinology & metabolism (31) 31
predictive value of tests (31) 31
care and treatment (30) 30
estradiol - blood (30) 30
research article (30) 30
tumors (30) 30
receptors, estrogen - analysis (29) 29
breast neoplasms - blood (28) 28
drug resistance, neoplasm (28) 28
estradiol (28) 28
neoadjuvant therapy (28) 28
risk (28) 28
triazoles - administration & dosage (27) 27
analysis (26) 26
animals (26) 26
aromatase inhibitor (26) 26
article (26) 26
breast (26) 26
disease-free survival (26) 26
gene expression regulation, neoplastic (26) 26
hormones (26) 26
medicine (26) 26
medicine & public health (26) 26
nitriles - administration & dosage (26) 26
randomized-trial (26) 26
apoptosis (25) 25
receptors, progesterone - metabolism (25) 25
biomarkers (24) 24
cell line, tumor (24) 24
genetic aspects (24) 24
resistance (24) 24
breast neoplasms - chemistry (23) 23
breast neoplasms - mortality (23) 23
drug therapy (23) 23
pathology (23) 23
biomarkers, tumor - metabolism (22) 22
body mass index (22) 22
gene-expression (22) 22
ki-67 antigen - analysis (22) 22
menopause (22) 22
proliferation (22) 22
time factors (22) 22
biomarkers, tumor - genetics (21) 21
breast neoplasms - surgery (21) 21
double-blind method (21) 21
ki-67 antigen - metabolism (21) 21
tamoxifen - administration & dosage (21) 21
antineoplastic agents - therapeutic use (20) 20
breast neoplasms - enzymology (20) 20
diagnosis (20) 20
genes (20) 20
growth (20) 20
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 07/2019, Volume 37, Issue 21, pp. 1842 - 1842
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 383, Issue 9922, pp. 1041 - 1048
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Summary Background Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall... 
Internal Medicine | SYSTEM | MEDICINE, GENERAL & INTERNAL | MULTICENTER | PHASE-3 TRIAL | OPEN-LABEL | RANDOMIZED CONTROLLED-TRIAL | PERTUZUMAB | Antineoplastic Agents, Immunological - administration & dosage | Trastuzumab - therapeutic use | Drug Administration Schedule | Follow-Up Studies | Biomarkers, Tumor - analysis | Humans | Middle Aged | Kaplan-Meier Estimate | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Antineoplastic Agents, Immunological - adverse effects | Breast Neoplasms - chemistry | Antineoplastic Agents, Immunological - therapeutic use | Breast Neoplasms - pathology | Chemotherapy, Adjuvant - methods | Adult | Female | Aged | Receptor, ErbB-2 - analysis | Heart Diseases - chemically induced | Antimitotic agents | Medical colleges | Analysis | Adjuvant treatment | Monoclonal antibodies | Breast cancer | Antineoplastic agents | Cancer | Heart | Laboratories | Toxicity | Medical services | Clinical trials | Cancer therapies | Incidence | Motivation | Failure analysis | Surgery | Heart diseases | Recombinant | Medical research | Health risks | Mammography | Radiation therapy | Patients | Survival | ErbB-2 protein | Chemotherapy | Breast | Informed consent | Trastuzumab | Schedules | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9897, pp. 1021 - 1028
Journal Article
Journal Article
1999, 1st ed., European School of Oncology scientific updates, ISBN 0444503277, Volume 4., x, 133
Book
Journal of the National Cancer Institute, ISSN 0027-8874, 10/2008, Volume 100, Issue 19, pp. 1380 - 1388
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 989 - 998
Journal Article